JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kjaer, A.
Right arrow Articles by Hesse, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kjaer, A.
Right arrow Articles by Hesse, B.
Journal of Nuclear Medicine Vol. 44 No. 1 19-23
© 2003 by Society of Nuclear Medicine


Clinical Investigations

Dipyridamole, Cold Pressor Test, and Demonstration of Endothelial Dysfunction: A PET Study of Myocardial Perfusion in Diabetes

Andreas Kjaer, MD, PhD, DMS1, Christian Meyer, MD, PhD1, Flemming S. Nielsen, MD, DMS2, Hans-Henrik Parving, MD, DMS2 and Birger Hesse, MD, DMS1

1 Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2 Steno Diabetes Center, Gentofte, Denmark

Much evidence suggests endothelial dysfunction to be present in non-insulin-dependent diabetes mellitus (NIDDM) and to be important for the development of myocardial ischemia. Endothelial function in the coronary vessels may be studied in various ways. We compared the effect of cold pressor testing (CPT) with that of dipyridamole, a pharmacologic vasodilator, on coronary blood flow (CBF) measured by PET in NIDDM patients and healthy volunteers. In addition, we studied the effect of acute angiotensin-converting enzyme (ACE) inhibition on the flow response. Methods: Ten NIDDM patients and 10 control subjects participated. Myocardial perfusion was determined at baseline, during CPT, and after dipyridamole infusion by PET using intravenous 13N-ammonia. Results: Resting CBF was similar in NIDDM patients and in control subjects. CPT increased CBF by 20% in the control group, whereas no increase was observed in the patients. After dipyridamole infusion, CBF increased 2- to 3-fold in patients and 3- to 4-fold in control subjects. The increase and maximal CBF were significantly higher in control subjects than in patients. During ACE-inhibitor infusion, which had no influence on resting CBF in patients or control subjects (n = 5), CPT increased CBF by 14% in the NIDDM group. After dipyridamole, CBF increased 3- to 4-fold in both groups. The increase in CBF and maximal CBF in the 2 groups were not different during ACE-inhibitor infusion. Conclusion: In these NIDDM patients without evidence of epicardial coronary disease, endothelial dysfunction is strongly suggested by an impaired increase in CBF both to dipyridamole and to CPT. This dysfunction was reversed by infusion of an ACE inhibitor. Although ACE inhibition during CPT did induce significant increases in CBF in the patients, the changes during ACE inhibition were small compared with the dipyridamole response, and the absence of CBF increase during CPT in 3 of the 10 control subjects further limits the value of CPT for the study of coronary endothelial dysfunction.

Key Words: cold pressor test • diabetes • endothelial dysfunction • myocardial perfusion • PET




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
F. M. Bengel, T. Higuchi, M. S. Javadi, and R. Lautamaki
Cardiac positron emission tomography.
J. Am. Coll. Cardiol., June 30, 2009; 54(1): 1 - 15.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. M. Madsen, H. M. Sondergaard, M. Bottcher, N. H. Buus, O. Schmitz, H. E. Botker, and T. T. Nielsen
Impact of Type 2 Diabetes on Nitric Oxide and Adrenergic Modulation of Myocardial Perfusion
Diabetes, February 1, 2007; 56(2): 468 - 475.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. Lautamaki, K.E. J. Airaksinen, M. Seppanen, J. Toikka, R. Harkonen, M. Luotolahti, R. Borra, J. Sundell, J. Knuuti, and P. Nuutila
Insulin Improves Myocardial Blood Flow in Patients With Type 2 Diabetes and Coronary Artery Disease
Diabetes, February 1, 2006; 55(2): 511 - 516.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. H. Marwick
Ischaemia and outcome with normal coronary arteries
Eur. Heart J., October 2, 2005; 26(20): 2077 - 2078.
[Full Text] [PDF]


Home page
JNMHome page
N. P. Johnson and K. L. Gould
Clinical Evaluation of a New Concept: Resting Myocardial Perfusion Heterogeneity Quantified by Markovian Analysis of PET Identifies Coronary Microvascular Dysfunction and Early Atherosclerosis in 1,034 Subjects
J. Nucl. Med., September 1, 2005; 46(9): 1427 - 1437.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. O. Prior, M. J. Quinones, M. Hernandez-Pampaloni, A. D. Facta, T. H. Schindler, J. W. Sayre, W. A. Hsueh, and H. R. Schelbert
Coronary Circulatory Dysfunction in Insulin Resistance, Impaired Glucose Tolerance, and Type 2 Diabetes Mellitus
Circulation, May 10, 2005; 111(18): 2291 - 2298.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.